Sidoti Has Bearish Estimate for Kamada FY2026 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Equities research analysts at Sidoti lowered their FY2026 earnings estimates for shares of Kamada in a report issued on Friday, September 25th. Sidoti analyst J. Sidoti now anticipates that the biotechnology company will earn $0.42 per share for the year, down from their previous estimate of $0.46. The consensus estimate for Kamada’s current full-year earnings is $0.48 per share. Sidoti also issued estimates for Kamada’s FY2027 earnings at $0.46 EPS.

Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.05. The firm had revenue of $54.92 million during the quarter, compared to analyst estimates of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%.

Several other equities research analysts have also recently issued reports on the stock. William Blair set a $15.00 price objective on shares of Kamada in a research report on Tuesday, July 21st. UBS Group reaffirmed a “buy” rating and set a $15.00 target price on shares of Kamada in a research note on Friday, September 18th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Kamada in a report on Tuesday, September 22nd. Benchmark reissued a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. Finally, Wall Street Zen upgraded Kamada from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $13.50.

Kamada Trading Down 2.6%

NASDAQ KMDA opened at $8.46 on Tuesday. Kamada has a 12 month low of $6.50 and a 12 month high of $9.35. The stock has a market cap of $486.49 million, a PE ratio of 22.26, a P/E/G ratio of 0.73 and a beta of 0.88. The stock’s 50 day moving average is $7.96 and its 200 day moving average is $7.89.

Institutional Trading of Kamada

A hedge fund recently raised its stake in Kamada stock. Aristides Capital LLC raised its position in shares of Kamada Ltd. (NASDAQ:KMDA) by 4.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,491 shares of the biotechnology company’s stock after acquiring an additional 1,476 shares during the period. Aristides Capital LLC owned approximately 0.06% of Kamada worth $288,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Cuts Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th were paid a $0.17 dividend. This represents a dividend yield of 206.0%. The ex-dividend date of this dividend was Thursday, August 27th. This is a decrease from Kamada’s previous annual dividend of $0.25. Kamada’s dividend payout ratio is 31.58%.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company focused on the development, manufacture and commercialization of plasma-derived and specialty pharmaceutical products. The company’s portfolio is aimed primarily at treating rare diseases and other conditions requiring replacement or immune-modulating therapies.

Kamada’s principal product is GLASSIA, an intravenous alpha-1 proteinase inhibitor used as augmentation therapy in adults with alpha-1 antitrypsin deficiency, a rare genetic disorder that can cause progressive lung disease.